IL-17 NanoAb

N/A

Report date: 2024/02/28 10:47:35

Base Information

Drug NameIL-17 NanoAb
Drug Alias Nameanti-IL-17 VHH antibodies
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionInterleukin 17A modulatorsInterleukin-17F modulators
TargetsInterleukin 17AInterleukin-17F
Therapy Area/IndicationsPsoriasisDermatitis, AtopicArthritis, Psoriatic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Medical Center GottingenThe Max Planck Society
China Registration ClassN/A

Develop Information

Active CompaniesScinai Immunotherapeutics Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisDermatitis, AtopicArthritis, Psoriatic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A